ArticleOncogene2006
ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Identifying novel regulatory effects for clinically relevant genes through the study of the Greek population.BMC genomics · 2023Article
- Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer.Frontiers in endocrinology · 2023Article
- Review
- MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation.Molecular oncology · 2021Article
- The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival.Scientific reports · 2016Article
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer research · 2014Article
- Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells.Journal of medicinal food · 2013Article
- CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.Clinical & developmental immunology · 2013Review
- A microarray analysis of gene expression patterns during early phases of newt lens regeneration.Molecular vision · 2013Article
- RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis.Molecular biology of the cell · 2011Article
- Localization and characterization of ST7 in cancer.Journal of cancer research and clinical oncology · 2011Article
- Article
- Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.Journal of lipid research · 2009Article
- Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.BMC systems biology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple lines of evidence have provided compelling evidence for the existence of a tumor suppressor gene (TSG) on chromosome 7q31.1. ST7 may be the target of this genetic instability but its designation as a TSG is controversial. In this study, we show that, functionally, ST7 behaves as a tumor suppressor in human cancer. ST7 suppressed growth of PC-3 prostate cancer cells inoculated subcutaneously into severe combined immunodeficient mice, and increased the latency of tumor detection from 13 days in control tumors to 23 days. Re-expression of ST7 was also associated with suppression of colony formation under anchorage-independent conditions in MDA-MB-231 breast cancer cells and ST7 mRNA expression was downregulated in 44% of primary breast cancers. Expression profiling of PC-3 cells revealed that ST7 predominantly induces changes in genes involved in re-modeling the extracellular matrix such as SPARC, IGFBP5 and several matrix metalloproteinases. These data indicate that ST7 may mediate tumor suppression through modification of the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.